{"anticipatedPostingDate":"2027-03","denomUnitsSelected":"Participants","description":"ORR per RECIST 1.1 assessed by BICR is defined as the percentage of participants with at least 1 visit response of CR or PR (i.e., unconfirmed response). CR is defined as disappearance of all TLs since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis diameter to \\<10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.","reportingStatus":"NOT_POSTED","timeFrame":"From date of randomization until death due to any cause, up to approximately 89 months","title":"Durvalumab Versus Durvalumab Plus Tremelimumab: Objective Response Rate Assessed by Blinded Independent Central Review Per Response Evaluation Criteria in Solid Tumors Version 1.1","type":"SECONDARY"}